← Back to Company DatabaseVisit Website
Kernal Biologics
In vivo CAR-T cell therapy via AI-designed mRNA and targeted LNPs.
Series ACambridge, MA
About
Kernal Biologics engineers cells inside the body using AI-designed selective mRNA and targeted lipid nanoparticle technology to create lower-cost in vivo CAR-T therapies. Their KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs for blood cancers. The company was awarded up to $48 million from ARPA-H to develop its in vivo CAR-T platform.
Total Funding
$73MKey Product
KR-402 in vivo CAR-T therapyGeography
North AmericaKey Investors
Hummingbird VenturesAmgen VenturesY Combinator
Focus Areas
Treatment (Therapeutics)Drug Discovery
Technology
Cell TherapyImmunotherapyAI / Machine Learning
Cancer Types
Blood Cancers
Last updated: Feb 4, 2026